On Wednesday, Shares of Intel Corporation (NASDAQ:INTC), gained 1.80% to $32.31. The stock attained the volume of 36.93 million shares.
The year-to-date (YTD) performance reflected a -8.90% below last year. During the past month the stock gains 9.56%, bringing three-month performance to 12.65% and six-month performance to 5.07%. The stock holds the market capitalization of 153.65B.
Wind River®, a global leader in delivering software for the Internet of Things (IoT), introduced the latest version of Wind River Linux. Wind River Linux 8 brings together the flexibility and interoperability of open source together with improved user experience and scalability for addressing the opportunities and challenges of IoT. The company also introduced new features for Wind River Open Virtualization.
The latest version of Wind River Linux delivers an improved out-of-the-box experience with a noteworthy reduction in set-up and installation time, allowing customers to start developing applications within minutes. It uses the latest kernel and toolchain from the forthcoming Yocto Project 2.0 release, Linux kernel 4.1, and GNU toolchain 5.2. Driving a broad ecosystem of silicon partners, Wind River Linux features hardware support for the latest Intel® architecture, in addition to ARM®, MIPS, and PowerPC®.
“Wind River Linux allows customers to extract vast amounts of business intelligence and value from their data, and supports devices of all sizes, architectures, and industries—from general purpose and high-performing real-time devices to carrier grade, virtualization, and highly secure military applications,” said Dinyar Dastoor, vice president and general manager of operating system platforms at Wind River. “With the latest version of Wind River Linux and our updated Open Virtualization profile, we are delivering a versatile and robust Linux offering to the market that is ideally suited for the development of IoT devices.”
Wind River, a wholly owned partner of Intel Corporation (INTC), is a global leader in delivering software for the Internet of Things. The company has been pioneering computing inside embedded devices since 1981, and its technology is found in more than 2 billion products.
Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD), surged 2.80% to $100.27, during its last trading session. The share price of this stock traded recently in a range of $97.50 to $100.79. The company now has a market value of $143.15 billion.
For this company, beta value at 0.83 represents it is more volatile to the shift in the market. If we take a look on its volatility, 3.57% was seen in a week and for the month it was 3.43%.
Gilead Sciences, Inc. (Nasdaq:GILD) declared that the U.S. Food and Drug Administration (FDA) has approved the use of Letairis® (ambrisentan) in combination with tadalafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Letairis is an endothelin receptor antagonist that was first approved in 2007 in the U.S. as monotherapy for PAH to improve exercise ability and delay clinical worsening. Tadalafil is a PDE5 inhibitor that was initially approved for PAH in the U.S. in 2009 to improve exercise ability.
“The evidence to support the use of ambrisentan and tadalafil in PAH is well-established, however an outstanding question has been whether combining these two medications up front may further delay the progression of this disease over the long term for patients who are newly starting PAH therapy,” said Ronald J. Oudiz, MD, Professor of Medicine, David Geffen School of Medicine at UCLA and Director, Liu Center for Pulmonary Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. “Based on the data supporting recently’s approval, we now know that patients receiving ambrisentan and tadalafil up front are less likely to experience disease progression or be hospitalized, and have more improvement in exercise ability than patients receiving either effective therapy alone. As such, this combination represents a new treatment strategy for patients living with this debilitating and life-threatening disease.”
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The companys products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Shares of Precision Drilling Corp (USA) (NYSE:PDS), inclined 8.11% to $5.20, during its last trading session. In the last trading session, the stock moved on high volume, trading at a volume of 8.36 M as compared to its average daily volume of 3.71 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 39.78% which was maintained at 17.65% in 1-month period.
Precision Drilling Corporation (“Precision”) (PD.TO)(PDS) intends to release its 2015 third quarter results before the market opens on Thursday, October 22, 2015 and has planned a conference call and webcast to start promptly at 12:00 Noon MT (2:00 p.m. ET) on the same day.
Precision Drilling Corporation provides oil and natural gas drilling and related services and products. The company operates through two segments, Contract Drilling Services; and Completion and Production Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
